Collegium Pharmaceutical Inc COLL Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Dreyer Scott

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-701

Price:

$21.18
Jan 07, 2021 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Purchase)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-16,042

Price:

--
Jan 07, 2021 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-16,042

Price:

$22.00
Jan 07, 2021 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

16,042

Price:

$5.73
Jan 04, 2021 (filed on Jan 06, 2021)

Insider Name:

Ciaffoni Joseph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,090

Price:

$20.03
Dec 03, 2020 (filed on Dec 07, 2020)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,967

Price:

$19.24
Nov 30, 2020 (filed on Dec 02, 2020)

Insider Name:

Ciaffoni Joseph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,672

Price:

$18.49
Nov 18, 2020 (filed on Nov 20, 2020)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Purchase)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-16,000

Price:

--
Nov 18, 2020 (filed on Nov 20, 2020)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

16,000

Price:

$5.73
Oct 15, 2020 (filed on Oct 16, 2020)

Insider Name:

Kuhlmann Shirley R.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-7,060

Price:

$20.82

Filings by filing date

Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Dreyer Scott

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-701

Price:

$21.18
Jan 07, 2021 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Purchase)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-16,042

Price:

--
Jan 19, 2018 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Purchase)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-3,336

Price:

--
Jan 07, 2021 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-16,042

Price:

$22.00
Jan 07, 2021 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

16,042

Price:

$5.73
Jan 19, 2018 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,336

Price:

$23.00
Jan 19, 2018 (filed on Jan 11, 2021)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

3,336

Price:

$5.73
Jan 04, 2021 (filed on Jan 06, 2021)

Insider Name:

Ciaffoni Joseph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,090

Price:

$20.03
Dec 03, 2020 (filed on Dec 07, 2020)

Insider Name:

Fleming Alison B

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,967

Price:

$19.24
Nov 30, 2020 (filed on Dec 02, 2020)

Insider Name:

Ciaffoni Joseph

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,672

Price:

$18.49

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	100 Technology Center Dr STOUGHTON MA 02072-4710
Tel:	N/A
Website:	www.collegiumpharma.com
IR:	See website

Key People

Michael Thomas Heffernan Chairman of the Board	Joseph J. Ciaffoni President, Chief Executive Officer, Director	Paul Brannelly Chief Financial Officer, Executive Vice President
Alison B. Fleming Executive Vice President, Chief Technology Officer	Shirley R. Kuhlmann Executive Vice President, General Counsel, Secretary	Scott Dreyer Executive Vice President, Chief Commercial Officer
Richard Malamut Executive Vice President and Chief Medical Officer

Business Overview

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Financial Overview

For the nine months ended 30 September 2020,Collegium Pharmaceutical Inc revenues increased 5% to$233.7M. Net income totaled $19.8M vs. loss of $20.5M.Revenues reflect Xtampza segment increase of 25% to $97.2M.Net Income reflects General and administrative - Balancingv decrease of 8% to $74.1M (expense), Research andDevelopment decrease of 29% to $4.5M (expense).

Employees:	255 as of Dec 31, 2019

Reporting Currency:	U.S. Dollars
Enterprise value:	$872.46M as of Sep 30, 2020
Annual revenue (TTM):	$307.95M as of Sep 30, 2020
EBITDA (TTM):	$87.22M as of Sep 30, 2020
Net annual income (TTM):	$17.59M as of Sep 30, 2020
Free cash flow (TTM):	-$286.16M as of Sep 30, 2020
Net Debt Last Fiscal Year:	$101.62M as of Sep 30, 2020
Shares outstanding:	34,582,324 as of Oct 31, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Collegium Pharmaceutical Inc (OQ:COLL)